Prometheus Unveils Novel Approach for Predicting Risk of Disease Progression in Patients with Crohn's Disease
SAN DIEGO, May 3 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings supporting a novel, algorithm-based biomarker test that helps clinicians effectively predict the risk of developing aggressive disease in patients with Crohn's disease.
In an oral presentation yesterday at Digestive Disease Week (DDW) in New Orleans, Dr. Gary Lichtenstein, Professor of Medicine, Director of the Inflammatory Bowel Disease Program at the Hospital of the University of Pennsylvania, reported results from a cross-sectional study in which six serologic markers and three genetic mutation markers were analyzed to help identify patients who are at risk for a more severe course of disease over time.
"There is growing evidence that biomarkers may provide clinical insight in predicting the probability of progression to an aggressive disease behavior," said Dr. Lichtenstein. "This study shows that by combining serologic and genetic (serogenetic) markers with clinical parameters, disease severity can be accurately predicted in patients with Crohn's disease to help physicians stratify the risk of disease progression and manage patients more effectively."
About Crohn's Disease
Crohn's disease is a chronic disorder that causes inflammation of the digestive or gastrointestinal tract. Symptoms of the disease include diarrhea, abdominal pain, fever and rectal bleeding. Crohn's disease is often expensive to treat because many patients may require long-term medical care, including multiple hospitalizations, surgeries and expensive therapeutics. The condition can be difficult to manage clinically and consumes a substantial amount of healthcare resources in terms of physician time, procedures and medications. Crohn's disease is estimated to affect between 400,000 and 600,000 individuals in North America.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.
SOURCE Prometheus Laboratories Inc.
You May Also Like